News | March 10, 2026
AbbVie reports promising early results for novel obesity therapy ABBV-295
ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks
ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks
SYNT-101 is a once-daily oral pill engineered to redirect nutrient absorption beyond the small intestine’s duodenum
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
The clinical program has benefited from extensive European Union support, including the IMI2 TRIC-TB and UNITE4TB projects, as well as funding from the EDCTP2 bEto-TB project
The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research
The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination therapy
The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue
The mPTP plays a key role in mitochondrial dysfunction, inflammation, and neuronal death in neurodegenerative diseases
Subscribe To Our Newsletter & Stay Updated
